These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1084 related articles for article (PubMed ID: 15128354)

  • 1. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
    Colombel JF; Loftus EV; Tremaine WJ; Pemberton JH; Wolff BG; Young-Fadok T; Harmsen WS; Schleck CD; Sandborn WJ
    Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
    Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Chen DM; Pritchard ML; Sandborn WJ
    Clin Gastroenterol Hepatol; 2006 May; 4(5):621-30. PubMed ID: 16678077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates?
    Canedo J; Lee SH; Pinto R; Murad-Regadas S; Rosen L; Wexner SD
    Colorectal Dis; 2011 Nov; 13(11):1294-8. PubMed ID: 20969715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for intra-abdominal septic complications after a first ileocecal resection for Crohn's disease: a multivariate analysis in 161 consecutive patients.
    Alves A; Panis Y; Bouhnik Y; Pocard M; Vicaut E; Valleur P
    Dis Colon Rectum; 2007 Mar; 50(3):331-6. PubMed ID: 17252288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study.
    Marchal L; D'Haens G; Van Assche G; Vermeire S; Noman M; Ferrante M; Hiele M; Bueno De Mesquita M; D'Hoore A; Penninckx F; Rutgeerts P
    Aliment Pharmacol Ther; 2004 Apr; 19(7):749-54. PubMed ID: 15043515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
    Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
    Schneeweiss S; Korzenik J; Solomon DH; Canning C; Lee J; Bressler B
    Aliment Pharmacol Ther; 2009 Aug; 30(3):253-64. PubMed ID: 19438424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?
    Gaertner WB; Decanini A; Mellgren A; Lowry AC; Goldberg SM; Madoff RD; Spencer MP
    Dis Colon Rectum; 2007 Nov; 50(11):1754-60. PubMed ID: 17899271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroids and poor nutrition are associated with infectious wound complications in children undergoing first stage procedures for ulcerative colitis.
    Markel TA; Lou DC; Pfefferkorn M; Scherer LR; West K; Rouse T; Engum S; Ladd A; Rescorla FJ; Billmire DF
    Surgery; 2008 Oct; 144(4):540-5; discussion 545-7. PubMed ID: 18847637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
    Baert F; Moortgat L; Van Assche G; Caenepeel P; Vergauwe P; De Vos M; Stokkers P; Hommes D; Rutgeerts P; Vermeire S; D'Haens G; ;
    Gastroenterology; 2010 Feb; 138(2):463-8; quiz e10-1. PubMed ID: 19818785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn's disease.
    El-Hussuna A; Andersen J; Bisgaard T; Jess P; Henriksen M; Oehlenschlager J; Thorlacius-Ussing O; Olaison G
    Scand J Gastroenterol; 2012 Jun; 47(6):662-8. PubMed ID: 22486168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery.
    Papay P; Reinisch W; Ho E; Gratzer C; Lissner D; Herkner H; Riss S; Dejaco C; Miehsler W; Vogelsang H; Novacek G
    Am J Gastroenterol; 2010 May; 105(5):1158-64. PubMed ID: 20010925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiopurine therapy is associated with postoperative intra-abdominal septic complications in abdominal surgery for Crohn's disease.
    Myrelid P; Olaison G; Sjödahl R; Nyström PO; Almer S; Andersson P
    Dis Colon Rectum; 2009 Aug; 52(8):1387-94. PubMed ID: 19617749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive therapy does not increase operative morbidity in patients with Crohn's disease.
    Bafford AC; Powers S; Ha C; Kruse D; Gorfine SR; Chessin DB; Bauer JJ
    J Clin Gastroenterol; 2013 Jul; 47(6):491-5. PubMed ID: 23090048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of ileocolic resection and right hemicolectomies for Crohn's patients in comparison with non-Crohn's patients and the impact of perioperative immunosuppressive therapy with biologics and steroids on inpatient complications.
    Mascarenhas C; Nunoo R; Asgeirsson T; Rivera R; Kim D; Hoedema R; Dujovny N; Luchtefeld M; Davis AT; Figg R
    Am J Surg; 2012 Mar; 203(3):375-8; discussion 378. PubMed ID: 22364904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease.
    Ochsenkühn T; Göke B; Sackmann M
    Am J Gastroenterol; 2002 Aug; 97(8):2022-5. PubMed ID: 12190171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
    Sandborn WJ; Hanauer SB
    Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
    Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
    Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.